• J. Cardiothorac. Vasc. Anesth. · Dec 2021

    Multicenter Study

    Outcome of Repeat Venoarterial Extracorporeal Membrane Oxygenation in Postcardiotomy Cardiogenic Shock.

    • Hakeem Yusuff, Fausto Biancari, Kristján Jónsson, Sigurdur Ragnarsson, Magnus Dalén, Thomas Fux, Angelo M Dell'Aquila, Antonio Fiore, Dario Di Perna, Giuseppe Gatti, Marco Gabrielli, Tatu Juvonen, Svante Zipfel, Karl Bounader, Andrea Perrotti, Antonio Loforte, Andrea Lechiancole, Marek Pol, Matteo Pettinari, Dieter De Keyzer, Henryk Welp, Daniele Maselli, Khalid Alkhamees, Vito G Ruggieri, and Giovanni Mariscalco.
    • Department of Intensive Care Medicine and Cardiac Surgery, Glenfield Hospital, University Hospitals of Leicester NHS Trust, Leicester, United Kingdom.
    • J. Cardiothorac. Vasc. Anesth. 2021 Dec 1; 35 (12): 3620-3625.

    ObjectiveData on patients requiring a second run of venoarterial extracorporeal membrane oxygenation (VA-ECMO) support in patients affected by postcardiotomy cardiogenic shock (PCS) are very limited. The authors aimed to investigate the effect of a second run of VA-ECMO on PCS patient survival.DesignRetrospective analysis of an international registry.SettingMulticenter study, tertiary university hospitals.ParticipantsData on adult PCS patients receiving a second run of VA-ECMO.Measurements And Main ResultsA total of 674 patients with a mean age of 62.9 ± 12.7 years were analyzed, and 21 (3.1%) patients had a second run of VA-ECMO. None of them required more than two VA-ECMO runs. The median duration of VA-ECMO therapy was 135 hours (interquartile range [IQR] 61-226) in patients who did not require a VA-ECMO rerun. In the rerun VA-ECMO group the median overall duration of VA-ECMO therapy was 183 hours (IQR 107-344), and the median duration of the first run was 114 hours (IQR 66-169). Nine (42.9%) of the patients who required a second run of VA-ECMO died during VA-ECMO therapy, whereas five (23.8%) survived to hospital discharge. No differences between patients treated with single or second VA-ECMO runs were observed in terms of hospital mortality and late survival. In patients requiring a second VA-ECMO run, the actuarial survival estimates at three and 12 months after VA-ECMO weaning were 23.8% ± 9.3% and 19.6% ± 6.4%, respectively.ConclusionsRepeat VA-ECMO therapy is a valid treatment strategy for PCS patients. Early and late survivals are similar between patients who have undergone a single or second run of VA-ECMO.Copyright © 2021 Elsevier Inc. All rights reserved.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…